Results 311 to 320 of about 3,722,377 (405)

T Cell Exhaustion in Cancer Immunotherapy: Heterogeneity, Mechanisms, and Therapeutic Opportunities

Advanced Science, EarlyView.
T cell exhaustion limits immunotherapy efficacy. This article delineates its progression from stem‐like to terminally exhausted states, governed by persistent antigen, transcription factors, epigenetics, and metabolism. It maps the exhaustion landscape in the TME and proposes integrated reversal strategies, providing a translational roadmap to overcome
Yang Yu, Xiaoyu Yao, Qingyang Wang, Mengrui Yang, Runze Li, Jiangjiang Qin, Jing Zhuang, Changgang Sun   +7 more
wiley   +1 more source

Preoperative Risk Stratification of Adnexal Masses Using the International Ovarian Tumor Analysis (IOTA) Simple Rules and Risk of Malignancy Index (RMI) 2: A Prospective Diagnostic Study From a Tertiary Centre in Southern India. [PDF]

Cureus
T K, Kathiresan S.
europepmc   +1 more source

Figure S1 from Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in <i>CCNE1</i>-Aberrant Ovarian and Endometrial Tumors

Nealia C. House, Victoria E. Brown, Maxine Chen, Liang Yuan, Sydney L. Moore, Jian Guo, Yoon Jong Choi, Lakshmi Muthuswamy, Scott Ribich, Philip Ramsden, L. Kerrie   +10 more
openalex   +1 more source

Exploring the Vasculitis‐Tumors Link: Epidemiological Patterns, Mechanistic Insights, and Clinical Implications

Advanced Science, EarlyView.
This review outlines association between vasculitis and malignancies and provides practical value for clinicians in distinguishing primary vasculitis from malignancy‐associated forms and optimizing patient surveillance, improving recognition of tumor‐associated vasculitis to reduce the risk of misdiagnosis, supporting more accurate clinical decision ...
Xiaofei Shi, Zhijiao Li, Xin Ma, Bei Zhang, Xinfeng Wu, Hua Fan, Rongzeng Liu, Hongwei Jiang, Cong‐Qiu Chu   +8 more
wiley   +1 more source

Loss of LATS1 and LATS2 promotes ovarian tumor formation by enhancing AKT activity and PD-L1 expression. [PDF]

Oncogene
Zhu Y, Abedini A, Rodriguez GM, McCloskey CW, Abou-Hamad J, Salah OS, Larocque J, Tsoi MF, Boerboom D, Cook D, Vanderhyden B.   +10 more
europepmc   +1 more source

Mapping CSC‐Mediated Ovarian Cancer Chemoresistance via CXCR4‐PET to Guide Precision Cisplatin Re‐Sensitization Therapy

Advanced Science, EarlyView.
CXCR4 functions as a potential cancer stem cell‐associated marker linked to chemoresistance in ovarian cancer, and an inhibitor of CXCR4, AMD3100, can enhance the cytotoxic response to cisplatin. Based on these findings, [68Ga]Ga‐Pentixafor positron emission tomography enables selective visualization of CXCR4‐high ovarian cancer, while AMD3100 combined
Lixia Feng, Simei Zhao, Zheng Wei, Wenwen Wang, Feiquan Ying, Lin Huang, Mengna Zhu, Mengqing Chen, Qiang Yang, Si Sun, Dawei Jiang, Lingling Gao, Jing Cai   +12 more
wiley   +1 more source

Case Report: Serous borderline ovarian tumor and extensive abdominopelvic endometriosis mimicking advanced epithelial ovarian cancer in a postmenopausal patient. [PDF]

Front Med (Lausanne)
Livatova K, Nguyen AD, Pizzuti J, Lee YC, McEachron J.   +4 more
europepmc   +1 more source

Engineered CAR‐NKT Extracellular Vesicles Suppress Tumor Progression and Enhance Antitumor Immunity

Advanced Science, EarlyView.
TM4SF1‐nanobody engineered CAR‐natural killer T–derived extracellular vesicles (CARTM4SF1‐EVs) provide a cell‐free alternative to CAR‐NKT therapy, achieving potent, targeted antitumor activity with reduced toxicity. CARTM4SF1‐EVs induce immunogenic cell death, remodel the tumor microenvironment, and enhance CD8⁺ T‐cell antitumor immunity.
Xiaopei Hao, Chengming Qu, Yanzhao Zhou, Xiaoqian Wang, Xiangjun Qian, Xun Chen, Feng Han, Xiaokai Zhang, Yiyi Ji, Han Li, ChengWei Ju, Peng Xia, Weiwei Tang, Hao Zhuang, Jinxue Zhou   +14 more
wiley   +1 more source

Giant mucinous borderline ovarian tumor: challenges of diagnosis and treatment. [PDF]

Arch Gynecol Obstet
Sadlecki P, Dejewska K, Domieracka P, Walentowicz-Sadlecka M.   +3 more
europepmc   +1 more source